The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Ovarian Neoplasms

 
 
 
 Sellar,  Contreras-Moreira,  Massie,  Scott,  Smyth,  Rabiasz,  Stronach,  Li,  Miller,  Gabra,  Watt,  Miller,  Brown,  Bates,  Williams,  Bertone,  Willett,  Hankinson,  Rosner,  Colditz,  Speizer,  Fuchs,  Hunter, Gottfried E. Konecny, Kanthinh Manivong, Boris Winterhoff, Charles Ginther, Judy Dering, Lynn C. Hartmann, Darren Riehle, Kimberly R. Kalli, William A. Cliby, Meenal Chalukya, Sophia Randolph, Teodora Kolarova, Guorong Yang, Maria Koehler, He-Jing Wang, Richard S. Finn, Siân Jones, Victor E. Velculescu, Dennis J. Slamon, Jingwei Qi, Lee Anderson, Resham Bhattacharya, Enfeng Wang, Sujata Patra, Viji Shridhar, Junhye Kwon, Priyabrata Mukherjee, Bushra Ali, Simon A. Gayther, Adele C. Green, Francesmary Modugno, Jonathan Beesley, Paul D. P. Pharoah, Claus Hogdall, Valerie McGuire, Marc T. Goodman, Jan Blaeker, David C. Whiteman, Jonathan Tyrer, Ian Jacobs, Fergus J. Couch, Thomas A. Sellers, Honglin Song, Jeffrey R. Marks, Montserrat Garcia-Closas, Julie M. Cunningham, Michael E. Carney, Beata Peplonska, Roberta B. Ness, Andrew Berchuck, Ellen L. Goode, Lydia Quaye, Estrid Hogdall, Louise Brinton, Alice S. Whittemore, Malcolm C. Pike, Susan J. Ramus, Richard DiCioccio, Kirsten B. Moysich, Danielle Shadforth, Bruce A. J. Ponder, Edwin S. Iversen, Douglas F. Easton, Penelope M. Webb, Robert P. Edwards, Jolanta Lissowska, Anna H. Wu, Susan Krüger Kjaer, Galina Lurie, Joellen Schildkraut, Georgia Chenevix-Trench, C. Leigh Pearce,  Lacey,  Troisi,  Hartge,  Mink,  Lubin,  Schairer,  Sherman,  Schatzkin,  Hughes-Davies,  Caldas,  Huntsman,  Milner,  Bye,  Hsu,  Ragaz,  Ruas,  Schuuring,  Brown,  Ponder,  Nielsen,  Linger,  Bentley,  Chin,  Schulzer,  Cattaneo,  Aparicio,  Fuks,  Chia,  Cahn,  Venkitaraman,  Ozdag,  Theillet,  Gilks,  Jordanova,  Doherty,  Ponting,  Kouzarides,  Yu, Honglin Song, Richard A. Dicioccio, Estrid Hogdall, Mitul Shah, Valerie McGuire, Lydia Quaye, Claus Hogdall, David Greenberg, Susan J. Ramus, Paul D. P. Pharoah, Susanne Kruger Kjaer, Simon A. Gayther, Douglas F. Easton, Alice S. Whittemore,  
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Ovarian Neoplasms

 

Psychiatry related information on Ovarian Neoplasms

 

High impact information on Ovarian Neoplasms

 

Chemical compound and disease context of Ovarian Neoplasms

 

Biological context of Ovarian Neoplasms

 

Anatomical context of Ovarian Neoplasms

 

Gene context of Ovarian Neoplasms

 

Analytical, diagnostic and therapeutic context of Ovarian Neoplasms

References

  1. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.F., Milner, J., Brown, L.A., Hsu, F., Gilks, B., Nielsen, T., Schulzer, M., Chia, S., Ragaz, J., Cahn, A., Linger, L., Ozdag, H., Cattaneo, E., Jordanova, E.S., Schuuring, E., Yu, D.S., Venkitaraman, A., Ponder, B., Doherty, A., Aparicio, S., Bentley, D., Theillet, C., Ponting, C.P., Caldas, C., Kouzarides, T. Cell (2003) [Pubmed]
  2. Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Bai, J., Uehara, Y., Montell, D.J. Cell (2000) [Pubmed]
  3. BRCA2 mutations in primary breast and ovarian cancers. Lancaster, J.M., Wooster, R., Mangion, J., Phelan, C.M., Cochran, C., Gumbs, C., Seal, S., Barfoot, R., Collins, N., Bignell, G., Patel, S., Hamoudi, R., Larsson, C., Wiseman, R.W., Berchuck, A., Iglehart, J.D., Marks, J.R., Ashworth, A., Stratton, M.R., Futreal, P.A. Nat. Genet. (1996) [Pubmed]
  4. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A., Franklin, E.W., Clarke-Pearson, D.L., Malviya, V.K., DuBeshter, B. N. Engl. J. Med. (1996) [Pubmed]
  5. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. Nussbaum, S.R., Gaz, R.D., Arnold, A. N. Engl. J. Med. (1990) [Pubmed]
  6. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M.J., Lynch, P., McTiernan, A., Offit, K., Perlman, J., Petersen, G., Thomson, E., Varricchio, C. JAMA (1997) [Pubmed]
  7. Prospective study of recreational physical activity and ovarian cancer. Bertone, E.R., Willett, W.C., Rosner, B.A., Hunter, D.J., Fuchs, C.S., Speizer, F.E., Colditz, G.A., Hankinson, S.E. J. Natl. Cancer Inst. (2001) [Pubmed]
  8. Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. DudokdeWit, A.C., Tibben, A., Duivenvoorden, H.J., Niermeijer, M.F., Passchier, J. J. Med. Genet. (1998) [Pubmed]
  9. Epidemiology of presenile Alzheimer's disease in Scotland (1974-88) I. non-random geographical variation. Whalley, L.J., Thomas, B.M., McGonigal, G., McQuade, C.A., Swingler, R., Black, R. The British journal of psychiatry : the journal of mental science. (1995) [Pubmed]
  10. An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer. Cruickshank, D.J., Paul, J., Lewis, C.R., McAllister, E.J., Kaye, S.B. Br. J. Cancer (1992) [Pubmed]
  11. Epithelial ovarian cancer: prevention, diagnosis, and treatment. Partridge, E.E., Barnes, M.N. CA: a cancer journal for clinicians. (1999) [Pubmed]
  12. Ovarian cancer, Part II. Barber, H.R. CA: a cancer journal for clinicians. (1980) [Pubmed]
  13. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Sellar, G.C., Watt, K.P., Rabiasz, G.J., Stronach, E.A., Li, L., Miller, E.P., Massie, C.E., Miller, J., Contreras-Moreira, B., Scott, D., Brown, I., Williams, A.R., Bates, P.A., Smyth, J.F., Gabra, H. Nat. Genet. (2003) [Pubmed]
  14. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Yajnik, V., Paulding, C., Sordella, R., McClatchey, A.I., Saito, M., Wahrer, D.C., Reynolds, P., Bell, D.W., Lake, R., van den Heuvel, S., Settleman, J., Haber, D.A. Cell (2003) [Pubmed]
  15. Treatment of ovarian cancer with intraperitoneal cisplatin. Beltran, M., Fuentes, R., Izquierdo, A. N. Engl. J. Med. (1997) [Pubmed]
  16. Acute leukemia after alkylating-agent therapy of ovarian cancer. Reimer, R.R., Hoover, R., Fraumeni, J.F., Young, R.C. N. Engl. J. Med. (1977) [Pubmed]
  17. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. Travis, L.B., Holowaty, E.J., Bergfeldt, K., Lynch, C.F., Kohler, B.A., Wiklund, T., Curtis, R.E., Hall, P., Andersson, M., Pukkala, E., Sturgeon, J., Stovall, M. N. Engl. J. Med. (1999) [Pubmed]
  18. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. van der Hoop, R.G., Vecht, C.J., van der Burg, M.E., Elderson, A., Boogerd, W., Heimans, J.J., Vries, E.P., van Houwelingen, J.C., Jennekens, F.G., Gispen, W.H. N. Engl. J. Med. (1990) [Pubmed]
  19. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Rogan, A.M., Hamilton, T.C., Young, R.C., Klecker, R.W., Ozols, R.F. Science (1984) [Pubmed]
  20. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Walker, G., MacLeod, K., Williams, A.R., Cameron, D.A., Smyth, J.F., Langdon, S.P. Clin. Cancer Res. (2007) [Pubmed]
  21. Role of hedgehog signaling in ovarian cancer. Bhattacharya, R., Kwon, J., Ali, B., Wang, E., Patra, S., Shridhar, V., Mukherjee, P. Clin. Cancer Res. (2008) [Pubmed]
  22. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Guo, Y., Nemeth, J., O'Brien, C., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H., Hornicek, F., Duan, Z. Clin. Cancer Res. (2010) [Pubmed]
  23. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Konecny, G.E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.J., Anderson, L., Kalli, K.R., Finn, R.S., Ginther, C., Jones, S., Velculescu, V.E., Riehle, D., Cliby, W.A., Randolph, S., Koehler, M., Hartmann, L.C., Slamon, D.J. Clin. Cancer Res. (2011) [Pubmed]
  24. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Vivas-Mejia, P.E., Rodriguez-Aguayo, C., Han, H.D., Shahzad, M.M., Valiyeva, F., Shibayama, M., Chavez-Reyes, A., Sood, A.K., Lopez-Berestein, G. Clin. Cancer Res. (2011) [Pubmed]
  25. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Simpkins, F., Hevia-Paez, P., Sun, J., Ullmer, W., Gilbert, C.A., da Silva, T., Pedram, A., Levin, E.R., Reis, I.M., Rabinovich, B., Azzam, D., Xu, X.X., Ince, T.A., Yang, J.Y., Verhaak, R.G., Lu, Y., Mills, G.B., Slingerland, J.M. Clin. Cancer Res. (2012) [Pubmed]
  26. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Gayther, S.A., Warren, W., Mazoyer, S., Russell, P.A., Harrington, P.A., Chiano, M., Seal, S., Hamoudi, R., van Rensburg, E.J., Dunning, A.M., Love, R., Evans, G., Easton, D., Clayton, D., Stratton, M.R., Ponder, B.A. Nat. Genet. (1995) [Pubmed]
  27. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Merajver, S.D., Pham, T.M., Caduff, R.F., Chen, M., Poy, E.L., Cooney, K.A., Weber, B.L., Collins, F.S., Johnston, C., Frank, T.S. Nat. Genet. (1995) [Pubmed]
  28. PIK3CA is implicated as an oncogene in ovarian cancer. Shayesteh, L., Lu, Y., Kuo, W.L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G.B., Gray, J.W. Nat. Genet. (1999) [Pubmed]
  29. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Gayther, S.A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B.A., Stratton, M.R., Easton, D. Nat. Genet. (1997) [Pubmed]
  30. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. Rubin, S.C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M.A., LiVolsi, V.A., Berchuck, A., Muto, M.G., Garber, J.E., Weber, B.L., Lynch, H.T., Boyd, J. N. Engl. J. Med. (1996) [Pubmed]
  31. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Anand, N., Murthy, S., Amann, G., Wernick, M., Porter, L.A., Cukier, I.H., Collins, C., Gray, J.W., Diebold, J., Demetrick, D.J., Lee, J.M. Nat. Genet. (2002) [Pubmed]
  32. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K.L., Daniel, B., Zimmermann, M.C., David, O., Burow, M., Gordon, A., Dhurandhar, N., Myers, L., Berggren, R., Hemminki, A., Alvarez, R.D., Emilie, D., Curiel, D.T., Chen, L., Zou, W. Nat. Med. (2003) [Pubmed]
  33. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Xu, Y., Shen, Z., Wiper, D.W., Wu, M., Morton, R.E., Elson, P., Kennedy, A.W., Belinson, J., Markman, M., Casey, G. JAMA (1998) [Pubmed]
  34. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. Hu, Y.L., Tee, M.K., Goetzl, E.J., Auersperg, N., Mills, G.B., Ferrara, N., Jaffe, R.B. J. Natl. Cancer Inst. (2001) [Pubmed]
  35. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Dinulescu, D.M., Ince, T.A., Quade, B.J., Shafer, S.A., Crowley, D., Jacks, T. Nat. Med. (2005) [Pubmed]
  36. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Chen, J., Silver, D.P., Walpita, D., Cantor, S.B., Gazdar, A.F., Tomlinson, G., Couch, F.J., Weber, B.L., Ashley, T., Livingston, D.M., Scully, R. Mol. Cell (1998) [Pubmed]
  37. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Hempel, N., How, T., Dong, M., Murphy, S.K., Fields, T.A., Blobe, G.C. Cancer Res. (2007) [Pubmed]
  38. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Gayther, S.A., Song, H., Ramus, S.J., Kjaer, S.K., Whittemore, A.S., Quaye, L., Tyrer, J., Shadforth, D., Hogdall, E., Hogdall, C., Blaeker, J., DiCioccio, R., McGuire, V., Webb, P.M., Beesley, J., Green, A.C., Whiteman, D.C., Goodman, M.T., Lurie, G., Carney, M.E., Modugno, F., Ness, R.B., Edwards, R.P., Moysich, K.B., Goode, E.L., Couch, F.J., Cunningham, J.M., Sellers, T.A., Wu, A.H., Pike, M.C., Iversen, E.S., Marks, J.R., Garcia-Closas, M., Brinton, L., Lissowska, J., Peplonska, B., Easton, D.F., Jacobs, I., Ponder, B.A., Schildkraut, J., Pearce, C.L., Chenevix-Trench, G., Berchuck, A., Pharoah, P.D. Cancer Res. (2007) [Pubmed]
  39. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Soegaard, M., Kjaer, S.K., Cox, M., Wozniak, E., Høgdall, E., Høgdall, C., Blaakaer, J., Jacobs, I.J., Gayther, S.A., Ramus, S.J. Clin. Cancer Res. (2008) [Pubmed]
  40. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Maehle, L., Apold, J., Paulsen, T., Hagen, B., Løvslett, K., Fiane, B., Van Ghelue, M., Clark, N., Møller, P. Clin. Cancer Res. (2008) [Pubmed]
  41. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Song, H., Hogdall, E., Ramus, S.J., Dicioccio, R.A., Hogdall, C., Quaye, L., McGuire, V., Whittemore, A.S., Shah, M., Greenberg, D., Easton, D.F., Kjaer, S.K., Pharoah, P.D., Gayther, S.A. Clin. Cancer Res. (2008) [Pubmed]
  42. hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer. Wittinger, M., Vanhara, P., El-Gazzar, A., Savarese-Brenner, B., Pils, D., Anees, M., Grunt, T.W., Sibilia, M., Holcmann, M., Horvat, R., Schemper, M., Zeillinger, R., Schöfer, C., Dolznig, H., Horak, P., Krainer, M. Clin. Cancer Res. (2011) [Pubmed]
  43. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., Clarke-Pearson, D.L., Davidson, M. N. Engl. J. Med. (1996) [Pubmed]
  44. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M., Ding, W. Science (1994) [Pubmed]
  45. Ovarian cancer. Effective treatment after alkylating-agent failure. Vogl, S.E., Greenwald, E., Kaplan, B.H., Moukhtar, M., Wollner, D. JAMA (1979) [Pubmed]
  46. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. Hankinson, S.E., Hunter, D.J., Colditz, G.A., Willett, W.C., Stampfer, M.J., Rosner, B., Hennekens, C.H., Speizer, F.E. JAMA (1993) [Pubmed]
  47. Menopausal hormone replacement therapy and risk of ovarian cancer. Lacey, J.V., Mink, P.J., Lubin, J.H., Sherman, M.E., Troisi, R., Hartge, P., Schatzkin, A., Schairer, C. JAMA (2002) [Pubmed]
 
WikiGenes - Universities